Published in J Exp Med on August 01, 1979
Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-alpha. J Clin Invest (1991) 2.14
Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest (1984) 1.72
Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood (2002) 1.64
Allogeneic induction of the human T cell-instructed monocyte procoagulant response is rapid and is elicited by HLA-DR. J Exp Med (1983) 1.60
The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol (1994) 1.53
Substance P-induced augmentation of cutaneous vascular permeability and granulocyte infiltration in mice is mast cell dependent. J Clin Invest (1989) 1.47
Fibrin-mediated protection against infection-stimulated immunopathology. J Exp Med (2003) 1.43
Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. Proc Natl Acad Sci U S A (1994) 1.36
Basophils and allergic inflammation. J Allergy Clin Immunol (2013) 1.29
Mast cell activation enhances airway responsiveness to methacholine in the mouse. J Clin Invest (1993) 1.26
Leukocyte interleukins induce cultured endothelial cells to produce a highly organized, glycosaminoglycan-rich pericellular matrix. J Cell Biol (1984) 1.23
Phenotypic and functional characterization of lymphocytes that bind human microvascular endothelial cells in vitro. Evidence for preferential binding of natural killer cells. J Clin Invest (1987) 1.14
Cloned LYT-2+ cytolytic T lymphocytes destroy allogeneic tissue in vivo. J Exp Med (1984) 1.07
Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1. J Exp Med (1996) 1.04
Structural and functional evolution of jejunal allograft rejection in rats and the ameliorating effects of cyclosporine therapy. J Clin Invest (1985) 0.96
Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol (1989) 0.95
Blood flow, histamine content and histidine decarboxylase activity in rat skin grafts and their modification by cyclosporin-A. Br J Pharmacol (1982) 0.93
Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. Proc Natl Acad Sci U S A (1997) 0.92
Lessons from cardiac transplantation in infancy. Pediatr Transplant (2009) 0.90
A controlled serial ultrastructural tracer study of first-set cardiac allograft rejection in the rat. Evidence that the microvascular endothelium is the primary target of graft destruction. Am J Pathol (1983) 0.89
T cell requirements for the rejection of renal allografts bearing an isolated class I MHC disparity. J Exp Med (1990) 0.88
Regulatory roles of T mu and T gamma cells in the collaborative cellular initiation of the extrinsic coagulation pathway by bacterial lipopolysaccharide. J Clin Invest (1985) 0.84
Mast Cells Contribute to Radiation-Induced Vascular Hyperpermeability. Radiat Res (2016) 0.82
Monokine induced by interferon-gamma (MIG/CXCL9) is derived from both donor and recipient sources during rejection of class II major histocompatibility complex disparate skin allografts. Am J Pathol (2009) 0.80
Pig but not human interferon-gamma initiates human cell-mediated rejection of pig tissue in vivo. Proc Natl Acad Sci U S A (1997) 0.80
Induction of delayed-type hypersensitivity responses to PPD: dendritic cells in synergy with 5-hydroxytryptamine can substitute for macrophages. Immunology (1988) 0.80
Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. Transpl Int (2015) 0.77
Postprimary Tuberculosis and Macrophage Necrosis: Is There a Big ConNECtion? MBio (2016) 0.76
In vivo observations of cell trafficking in allotransplanted vascularized skin flaps and conventional skin grafts. J Plast Reconstr Aesthet Surg (2009) 0.76
Short-term lymphokine stimulation of human peripheral blood mononuclear cells generates cytolytic activity against endothelial cells: involvement of natural killer cells. Immunology (1988) 0.75
Immunoelectron microscopic analysis of Ia antigen expression in rat skin during limb allograft rejection. Am J Pathol (1990) 0.75
Immunologically nonspecific mechanisms of tissue destruction in the rejection of skin grafts. J Exp Med (1994) 0.75
The behaviour and fate of skin autografts and skin homografts in rabbits: A report to the War Wounds Committee of the Medical Research Council. J Anat (1944) 16.73
Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. Adv Immunol (1974) 11.12
A simple micro cytotoxicity test. Transplantation (1969) 3.67
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
MECHANISM OF REJECTION OF HOMOTRANSPLANTED KIDNEYS. Nature (1963) 2.75
Lymphocytes and transplantation immunity. Adv Immunol (1967) 2.73
"Intrinsic" immunological tolerance in allophenic mice. Science (1967) 2.10
Determination of survival time of skin homografts in the rat by observation of vascular changes in the graft. Plast Reconstr Surg (1946) (1953) 2.09
Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity. J Immunol (1975) 1.98
Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
AN ELECTRON MICROSCOPIC STUDY OF THE HOMOGRAFT REACTION. Am J Pathol (1964) 1.58
The vascularization of skin autografts and homografts; an experimental study in man. Ann Surg (1956) 1.53
Loss of cell surface material from peritoneal exudate cells associated with lymphocyte-mediated inhibition of macrophage migration from capillary tubes. Lab Invest (1972) 1.41
Eosinophile in human skin homografting. Proc Soc Exp Biol Med (1953) 1.37
The cellular basis of allograft rejection in vivo. I. The cellular requirements for first-set rejection of heart grafts. J Exp Med (1978) 1.30
Role of the basophilic leukocyte in allograft rejection. J Immunol (1971) 1.26
Histocompatibility antigens on melanoblasts and hair follicle cells. Cell-localized homograft rejection in allophenic skin grafts. Transplantation (1970) 1.24
The pattern of rejection in rat skin homografts, and its relation to the vascular network. Lab Invest (1963) 1.22
Degranulation of basophilic leukocytes in allergic contact dermatitis reactions in man. J Immunol (1976) 1.18
Cytotoxic effects of peritoneal neutrophils on a syngeneic rat tumour. Nat New Biol (1972) 1.16
The rejection of skin homografts in the normal human subject. II. Histological findings. J Clin Invest (1962) 1.13
T-cell migration into allografts. J Exp Med (1975) 1.12
Histocompatibility types and measles antibodies in multiple sclerosis and optic neuritis. J Neurol Sci (1974) 1.05
Further studies on the phenomenon of pigment spread in guinea pigs' skin. Ann N Y Acad Sci (1963) 1.00
Detection of an allelic difference at a single gene locus in a small fraction of a large tumour-cell population. Nature (1956) 0.99
A histological study of the human skin graft. Am J Pathol (1961) 0.98
The microcirculatory events within full-thickness skin allografts (homografts) in mice. Surgery (1969) 0.90
Studies on the migratory behavior of melanocytes in guinea pig skin. J Exp Med (1970) 0.88
Thickening of arterial intima in rat cardiac allografts. A light and electron microscopic study. Am J Pathol (1971) 0.88
Pathogenesis of vascular injury in rejecting rat renal allografts. Johns Hopkins Med J (1977) 0.86
The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med (1991) 26.50
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Separation of caveolae from associated microdomains of GPI-anchored proteins. Science (1995) 5.25
Professional uncertainty and the problem of supplier-induced demand. Soc Sci Med (1982) 5.20
Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell (1992) 4.90
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med (1992) 4.39
Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature (1990) 4.21
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 4.12
Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev (1993) 3.96
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol (1994) 3.76
Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature (1981) 3.71
Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol (1989) 3.44
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42
Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol (1999) 3.42
Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res (1990) 3.35
Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med (1991) 3.15
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med (1994) 3.09
Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol (1988) 3.06
Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J Exp Med (1989) 3.03
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res (1993) 2.98
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol (1995) 2.96
Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest (2000) 2.92
A study of medical injury and medical malpractice. N Engl J Med (1989) 2.90
GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol (2000) 2.86
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol (1993) 2.85
Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature (1998) 2.82
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Pulmonary responses to bronchoconstrictor agonists in the mouse. J Appl Physiol (1985) (1988) 2.64
Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics (1989) 2.61
Cutaneous basophil hypersensitivity. II. A light and electron microscopic description. J Exp Med (1970) 2.61
Neutrophils emigrate from venules by a transendothelial cell pathway in response to FMLP. J Exp Med (1998) 2.61
Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res (1999) 2.55
Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med (1994) 2.54
Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol (1999) 2.50
IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med (1997) 2.48
Identification of adverse events occurring during hospitalization. A cross-sectional study of litigation, quality assurance, and medical records at two teaching hospitals. Ann Intern Med (1990) 2.48
Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med (2000) 2.46
Mast cells as a source of multifunctional cytokines. Immunol Today (1990) 2.46
Cytochemical localization of certain phosphatases in Escherichia coli. J Bacteriol (1970) 2.43
Mouse splenic and bone marrow cell populations that express high-affinity Fc epsilon receptors and produce interleukin 4 are highly enriched in basophils. Proc Natl Acad Sci U S A (1991) 2.41
Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta (1989) 2.40
Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol (2001) 2.38
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res (1996) 2.36
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
Melanoma in children. N Engl J Med (1995) 2.35
Benign cutaneous adnexal tumors with combined folliculosebaceous, apocrine, and eccrine differentiation. Clinicopathologic and immunohistochemical study of eight cases. Am J Dermatopathol (1996) 2.30
Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med (1996) 2.26
Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol (1991) 2.26
Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res (1995) 2.24
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS (1997) 2.24
Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci U S A (1988) 2.22
Cutaneous basophil hypersensitivity. I. A new look at the Jones-Mote reaction, general characteristics. J Exp Med (1970) 2.21
Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest (1987) 2.20
Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci U S A (1991) 2.17
The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol (1996) 2.15
Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol (1979) 2.15
Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-alpha. J Clin Invest (1991) 2.14
Regulation of extravascular coagulation by microvascular permeability. Science (1985) 2.11
Regulation of mast cell survival by IgE. Immunity (2001) 2.11
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol (1982) 2.10
An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol (2001) 2.10
Osteopontin expression and distribution in human carcinomas. Am J Pathol (1994) 2.09
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06
Genetically mast-cell-deficient W/Wv and Sl/Sld mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo. Am J Pathol (1987) 2.05
Human eosinophils express transforming growth factor alpha. J Exp Med (1990) 2.04